Advancements in Personalized Cellular Immunotherapy
Academic Press Inc (Verlag)
978-0-443-27731-3 (ISBN)
- Noch nicht erschienen (ca. August 2026)
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Arun Kumar Singh has completed M. Pharm (Pharmaceutics) from Galgotias University, Greater Noida, India. Mr. Singh joined as an assistant professor in the Department of Pharmacy, Vivekanand Global University Jaipur Rajasthan 303012. His area of interest is in the area of nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored one book with IOP publishing and has published 5 chapters in big data with River Publisher in Denmark. He has also published 20 review papers among which two are in Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. He has published 26 books with various publishers like IOP, Elsevier, CRC PRESS, and Wiley. Dr. Murali Yallapu is a tenured Associate Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology, and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews, with his work cited over 16,156 times. His primary research focuses on developing nanomaterials for enhanced therapeutic potential and cancer immunotherapy. Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical Journal Dr. Pranav Kumar Prabhakar is currently working as a Professor in the Department of Biotechnology at Nagaland University, Kohima, Nagaland, India. He has been listed among the World’s Top 2% Scientists (as published by Stanford University, USA, in 2021, 2022, 2023, and 2024). He earned his PhD in Biotechnology from IIT Madras. His primary research interests include elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He also serves as an editorial board member and reviewer for several reputed national and international journals. Dr. Pranav has received various honors, including a travel grant to attend ATTD 2009 in Greece, sponsored by the Indian Institute of Technology Madras and the Council for Scientific and Industrial Research (CSIR), and approved by the Department of Science and Technology (DST). He has published over 115 research articles in journals, authored or edited 17 books, contributed more than 40 book chapters, and delivered 9 oral and poster presentations at scientific meetings.
1. Introduction to Personalized Cellular Immunotherapy
2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy
3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy
4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues
5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives
6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors
7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies
8. The future of cancer immunotherapy: combining gene and cellular approaches
9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies
10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment
11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy
12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy
13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy
14. Combination therapy: a new strategy to manage cancer
15. Future perspective of cellular immunotherapy in cancer treatment
| Erscheint lt. Verlag | 1.8.2026 |
|---|---|
| Verlagsort | San Diego |
| Sprache | englisch |
| Maße | 191 x 235 mm |
| Gewicht | 450 g |
| Themenwelt | Naturwissenschaften ► Biologie |
| ISBN-10 | 0-443-27731-1 / 0443277311 |
| ISBN-13 | 978-0-443-27731-3 / 9780443277313 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
